Vimarsana
Biggest News Aggregation in the World

Page 6 - Mori Arkin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mori Arkin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mori Arkin Today - Breaking & Trending Today

Hedge Funds Are Coming Back To Fiverr International Ltd. (FVRR) - Vimarsana News

Hedge Funds Are Coming Back To Fiverr International Ltd. (FVRR)

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.

Uniqure NV (QURE): Hedge Funds Are Snapping Up - Vimarsana News

Uniqure NV (QURE): Hedge Funds Are Snapping Up

A whopping number of 13F filings filed with U.S.

Hedge Funds Are Betting On Xenon Pharmaceuticals Inc (XENE) - Vimarsana News

Hedge Funds Are Betting On Xenon Pharmaceuticals Inc (XENE)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

Is Nurix Therapeutics, Inc. (NRIX) A Good Stock To Buy? - Vimarsana News

Is Nurix Therapeutics, Inc. (NRIX) A Good Stock To Buy?

Is Nurix Therapeutics, Inc. (NRIX) A Good Stock To Buy? In this article we are going to use hedge fund sentiment as a tool and determine whether Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds’ picks do...

Perrigo sells generics division for $1.55b to Altaris - Vimarsana News

Perrigo sells generics division for $1.55b to Altaris

Perrigo sells generics division for $1.55b to Altaris Perrigo will now have no activities in Israel. The sale threatens 850 jobs in the Negev and the company might delist from the TASE. Perrigo Company (NYSE:PRGO; TASE:PRGO) announced today that it has reached a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners LLC for $1.55 billion, including $1.5 billion in cash. As part of the consideration, Altaris will also assume more than $50 million in potential R&D milestone payments and contingent purchase obligations with third-party Rx partners. The d...